Published in final edited form as:

Methods Mol Biol. 2016 ; 1400: 139–156. doi:10.1007/978-1-4939-3372-3_10.

LINE-1 Cultured Cell Retrotransposition Assay

Huira C. Kopera^{1,*}, Peter A. Larson¹, John B. Moldovan², Sandra R. Richardson¹, Ying Liu⁴, and John V. Moran^{1,2,3,4,*}

¹Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA

²Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, MI, USA

³Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

⁴Howard Hughes Medical Institute, Chevy Chase, MD, USA

Summary

The Long Interspersed Element-1 (LINE-1 or L1) retrotransposition assay has facilitated the discovery and characterization of active (*i.e.*, retrotransposition-competent) LINE-1 sequences from mammalian genomes. In this assay, an engineered LINE-1 containing a retrotransposition reporter cassette is transiently transfected into a cultured cell line. Expression of the reporter cassette, which occurs only after a successful round of retrotransposition, allows the detection and quantification of the LINE-1 retrotransposition efficiency. This assay has yielded insight into the mechanism of LINE-1 retrotransposition. It also has provided a greater understanding of how the cell regulates LINE-1 retrotransposition and how LINE-1 retrotransposition impacts the structure of mammalian genomes. Below, we provide a brief introduction to LINE-1 biology and then detail how the LINE-1 retrotransposition assay is performed in cultured mammalian cells.

Keywords

LINE-1; Alu; retrotransposition assay; *trans*-complementation assay; mammalian cultured cells

1. Introduction

Sequences derived from Long Interspersed Element-1 (LINE-1 or L1) comprise approximately 17% of human genomic DNA (1). Although greater than 99.9% of human L1s have been rendered inactive by mutational processes, a small cohort of active L1s can move to new genomic locations by a “copy-and-paste” process known as retrotransposition (reviewed in (2)). Here, we refer to these L1s as retrotransposition-competent or RC-L1s.

A full-length RC-L1 is ~6 kb in length. Human RC-L1s contain a 5' untranslated region (UTR), two non-overlapping open reading frames (ORFs) that are separated by a short 63 bp inter-ORF sequence, and a 3'UTR that ends in an adenosine-rich tract (3, 4). The human L1 5'UTR contains an internal RNA polymerase II promoter that directs the initiation of

*Corresponding authors: chongh@umich.edu and moranj@umich.edu.

transcription at or near the first base of the element (5–7); it also has an ill-defined anti-sense promoter (8). L1 ORF1 encodes an ~40 kDa RNA binding protein (ORF1p) that has nucleic acid chaperone activity (9–17). ORF2 encodes an ~150 kDa protein (ORF2p) that has endonuclease (EN) and reverse transcriptase (RT) activities that are critical for retrotransposition (18–25). ORF2p also contains a cysteine-rich domain (C) that is required for retrotransposition, although its function requires elucidation (24, 26). The L1 3'UTR contains a guanosine-rich polypurine tract, a weak RNA polymerase II polyadenylation signal, and ends in an A-rich tract (27–30). Experiments in cultured cells have demonstrated that the L1 3'UTR is not strictly required for retrotransposition (18, 24).

L1 elements retrotranspose by target site-primed reverse transcription (TPRT) (20, 31, 32). As a result of TPRT, genomic L1s typically have the following structural hallmarks: 1) they are truncated at their 5' ends; 2) they are flanked by target-site duplications (TSDs) that vary both in their length and sequence; 3) they end in an A-rich tract; and 4) they generally insert into an L1 ORF2p endonuclease consensus cleavage site (5'-TTTT/A-3' and variations of that sequence, where "/" denotes the endonucleolytic nick) (1, 33–40).

The proteins encoded by L1s (ORF1p and/or ORF2p) occasionally act *in trans* to retrotranspose Short INterspersed Element (SINE) RNAs (*e.g.*, the RNAs transcribed from Alu and SINE-VNTR-Alu (SVA) elements), non-coding RNAs (*e.g.*, uracil-rich small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs)), and RNA polymerase II transcribed messenger RNAs (mRNAs) (41–51). In aggregate, these sequences comprise at least ~11% of human genomic DNA ((1), reviewed in (2)). Thus, LINE-1 mediated retrotransposition events account for approximately one-third, or one billion base pairs of human genomic DNA. Ongoing LINE-1 retrotransposition continues to affect both inter- and intra-individual human genetic diversity and has caused ~100 sporadic cases of genetic disease ((52), reviewed in (2, 53)).

The development of the cultured cell retrotransposition assay represented a seminal moment in LINE-1 biology because it allowed the experimental study of LINE-1 retrotransposition in "real time" (24). The rationale of the assay built upon experimental strategies to examine retrotransposon mobility in yeast and mammalian cells (54–57). Briefly, a retrotransposition indicator cassette was introduced into the L1 3'UTR in the opposite orientation of the L1 transcript (24). The reporter cassette consists of a reporter gene (*e.g.*, neomycin phosphotransferase in the *neoI* reporter cassette) equipped with a heterologous promoter and polyadenylation signal (Figure 1A). The reporter gene is interrupted by an intron that is in the same orientation with respect to L1 transcription. Thus, the reporter gene can only be expressed upon transcription of the L1, splicing of the intron in the reporter cassette, and the reverse transcription of the L1 RNA to introduce a new L1 copy and the reporter cassette into the genome (24). Once integrated into the genome, cells harboring new retrotransposition events can be identified by either selecting or screening for reporter gene expression. The number of colonies or cells expressing the reporter genes allows the quantification of the LINE-1 retrotransposition efficiency.

Since the initial publication of the LINE-1 retrotransposition assay (24), several adaptations have made the assay more efficient (58) and applicable to study an array of biological

questions. For example, the *mneoI* cassette and a derivative of the cassette, *neo^{Tet}*, which allows the detection of a retrotransposed RNA polymerase III transcribed RNA, have been used to study the retrotransposition of Alu and SVA SINE RNAs, U6 snRNA, and cellular mRNAs (33, 43, 45–47, 49, 51). Modified versions of the *mneoI* cassette have been used to recover LINE-1 retrotransposition events from genomic DNA, enabling detailed analyses of how LINE-1 retrotransposition events impact the genome (33, 34, 38). Indeed, these studies revealed that *de novo* retrotransposition events from engineered L1 constructs resemble endogenous L1 insertions in their structure. Moreover, they revealed that L1 is not simply an insertional mutagen and that LINE-1 retrotransposition events can generate intra-chromosomal deletions, intra-chromosomal duplications, and perhaps inter-chromosomal translocations (33, 34, 38).

Other variations on the retrotransposition reporter cassette include incorporation of an enhanced green fluorescent protein (EGFP) reporter gene (*mEGFP1*), which has been used to assay LINE-1 retrotransposition both *in vitro* and *in vivo* (59–66). The subsequent development of the blasticidin S-resistance reporter cassette (*mblast1*) was used to examine DNA repair deficient Chinese hamster ovary (CHO) cell lines for retrotransposition (36, 67–69). Blasticidin S kills cells more efficiently than G418 and may be used for cell lines that have a high tolerance for G418. More recently, luciferase-based retrotransposition indicator cassettes, which may be amenable for high-throughput screening, have been developed to assay for retrotransposition (70).

In sum, the LINE-1 cultured cell retrotransposition assay has been used successfully in multiple human and other mammalian cell lines (summarized in (71)). The following protocol has been adapted from previously published assays (24, 36, 43, 58, 66) and is optimized for HeLa cells. Importantly, the necessary experimental controls required to correctly interpret retrotransposition assay results (*e.g.*, transfection efficiency, cell viability, and off-target effects) are highlighted in the Notes section of this protocol.

2. Materials

2.1 Cell Culture Medium and Transfection Reagents

1. Two clonal HeLa cell lines support retrotransposition. HeLa-JVM cells are used to assay LINE-1 retrotransposition (24). HeLa-HA are used to assay either LINE-1 or Alu retrotransposition (72).
2. Cultured cell growth medium for HeLa cells
 - a. To assay LINE-1 retrotransposition (*in cis*), HeLa-JVM cells are grown in DMEM (4.5 g/L D-glucose, Life Technologies #11960-051) containing 10% FBS (Sigma #F2442 or Life Technologies #26140-079), and 1× Pen Strep Glutamine (100 U/mL penicillin, 100 µg/mL streptomycin, and 292 µg/mL glutamine, Life Technologies #10378-016). This is called HeLa-JVM DMEM growth medium in the protocol below.

- b. To assay Alu retrotransposition (*in trans*), HeLa-HA cells are grown in MEM (with Earle's salts, Life Technologies #11090-073) containing 10% FBS (Sigma #F2442 or Life Technologies #26140-079), 1× MEM Non-Essential Amino Acids (Life Technologies #11140-050), and 1× Pen Strep Glutamine (100 U/mL penicillin, 100 µg/mL streptomycin, and 292 µg/mL glutamine, Life Technologies #10378-016). This is called HeLa-HA MEM growth medium in the protocol below.
3. 1× phosphate-buffer saline (PBS), pH 7.4, sterilized
4. 0.05% Trypsin-EDTA (Life Technologies, #25300-054)
5. A cell counter (*e.g.*, Countess® Automated Cell Counter, Life Technologies #C10227) or a hemocytometer
6. Tissue culture dishes or flasks (Corning 6-well plates (#353046) and T-75 flasks (#353136) or 10 cm dishes (#430293))
7. FuGene® 6 transfection reagent (Promega #E2691)
8. Opti-Mem® I (Life Technologies #31985-062)
9. Geneticin® (G418, 50 mg/mL stock, Life Technologies #10131-035), blasticidin S-HCl (10 mg/mL stock, Life Technologies #A11139-03), or puromycin (10 mg/mL stock, Sigma #P8833)
10. A flow cytometer (*e.g.*, the Accuri C6 Flow Cytometer (BD Biosciences))

2.2 Plasmids

1. To assay LINE-1 retrotransposition, *in cis* (Figure 1):
 - a. The pCEP4 mammalian expression episomal plasmid (Life Technologies), which generally is the backbone of the LINE-1 expression plasmids
 - b. A LINE-1 expression plasmid that is tagged with a retrotransposition reporter cassette (*e.g.*, pJM101/L1.3 (*mneoI*), pJJ101/L1.3 (*mblastI*), or pLRE3-mEGFP1 (*mEGFP1*) (67, 73–76))
 - c. A reporter plasmid (*e.g.*, hrGFP (Agilent)) to monitor transfection efficiency
 - d. A plasmid expressing a cDNA of interest. This plasmid should not contain the same selectable marker as the L1 reporter cassette.
2. To assay Alu retrotransposition, *in trans* (Figure 2):
 - a. A “reporter” retrotransposition plasmid that contains an Alu element and a modified *mneoI* cassette (*e.g.*, pAlu-

- neo^{Tet}) that allows the detection of a retrotransposed RNA polymerase III transcribed RNA (43)
- b. A “driver” LINE-1 expression plasmid (*i.e.*, either a full-length LINE-1 or a plasmid that expresses LINE-1 ORF2p (*e.g.*, pJM101/L1.3 neo or pCEP5'UTR-ORF2p neo (51, 77)) that lacks the retrotransposition reporter cassette
 - c. A reporter plasmid (*e.g.*, hrGFP) to monitor transfection efficiency
3. To test if cellular proteins affect LINE-1 retrotransposition (Figure 3; (78–80)):
- a. A LINE-1 expression plasmid that is tagged with a retrotransposition reporter cassette (*e.g.*, *mneoI*, *mblastI*, or *mEGFP1*)
 - b. A non-LINE-1 control plasmid (*e.g.*, pU6iNEO (79)) that expresses an intact (*i.e.*, intronless) version of the same selectable or screenable marker present in the LINE-1 retrotransposition reporter cassette
 - c. An expression vector containing the cDNA that is being tested for its effect on retrotransposition (*e.g.*, pK_A3A that expresses APOBEC3A (78, 79))
 - d. A negative control cDNA expression vector that expresses a protein that does not significantly affect retrotransposition (*e.g.*, pK_β-arrestin) (78, 79))

2.3 Fixing and Staining

1. Fix: 2% formaldehyde, 0.2% glutaraldehyde, in 1× PBS, pH 7.4
2. Stain (can use any one of the three):
 - a. 0.1% bromophenol blue, weight to volume (w/vol) in H₂O
 - b. 0.1% crystal violet blue, w/vol in H₂O
 - c. 0.4% Giemsa, w/vol in H₂O

3. Methods

Standard practices for handling cultured cells should be applied, such as use of laminar flow biosafety hoods and sterile techniques for all reagents. The transfection efficiency and the concentration of drugs used for genetic selection should first be optimized for each cell type used in this assay. The rationale and a timeline of the assay are presented in Figure 1. Cultured cell lines are routinely verified/authenticated by short tandem repeat (STR) analyses and checked for mycoplasma to ensure their integrity and lack of contamination, respectively.

3.1 LINE-1 retrotransposition assay in HeLa-JVM cells (*in cis*)

1. Day 1 - Plate cells: Seed 2×10^4 HeLa-JVM cells in each well of a 6-well tissue culture plate in HeLa-JVM DMEM growth media. Cells are grown in a humidified incubator at 37°C with 7% CO₂ (see Note 1).
2. Day 2 – Transfect cells: Cells typically are transfected 14 to 16 hours post-plating, day zero (d0) (Figure 1B), using the FuGENE® 6 transfection reagent following the manufacturer's instructions. Every retrotransposition assay should include the following transfection conditions: 1) a vector-only (pCEP4) or mock transfection; 2) a wild type LINE-1 retrotransposition plasmid (*e.g.*, pJM101/L1.3, pJJ101/L1.3, or pLRE3-*mEGFP1*), which serves as a positive control; and 3) a mutant LINE-1 plasmid (*e.g.*, pJM105/L1.3 has a mutation in the RT domain of L1 (51)), which serves as a negative control. To assay for retrotransposition, prepare a transfection mix in a 1.5 mL microcentrifuge tube containing 1 µg pCEP4 or an LINE-1 expression plasmid (Figure 1A) and 3 to 4 µL of FuGENE® 6 in 100 µL of Opti-Mem® I. Incubate the solution at room temperature for 20 minutes. Add the transfection mix to the growth medium of one well of cells in a 6-well tissue culture plate. To determine the transfection efficiency, prepare an additional transfection mix(es) in a 1.5 mL microcentrifuge tube containing 1 µg pCEP4 or a LINE-1 expression plasmid, 0.5 µg of an hrGFP expression plasmid, and 4 to 6 µL of FuGENE® 6 in 100 µL of Opti-Mem® I. Incubate the solution for 20 minutes at room temperature. Then, add the transfection mix to the growth medium of one well of cells in a 6-well tissue culture plate; these transfections will be used to calculate transfection efficiencies. Transfect three wells in each plate for each transfection condition to yield three technical replicates. It is important to calculate transfection efficiency and adjust retrotransposition assay results for each L1 plasmid individually, as subtle differences in L1 plasmid size and transfection mix composition can affect transfection efficiency. These differences could impact the final result of the retrotransposition assay (see Note 2).
3. Day 3 – Stop the transfection: Approximately 16 to 24 hours post-transfection, one day post-transfection (d1) (Figure 1B), aspirate the medium from the cells and add fresh HeLa-JVM DMEM growth medium to the cells.

¹Each cell line must be optimized for cell plating density, plasmid concentrations, transfection reagents, and the drug concentration needed for selection. The experiment also can be scaled-up into flasks:

- a. For 75 cm² flasks: transfect 2×10^6 cells with 8 µg DNA, 32 µL FuGENE® 6, and 500 µL of Opti-Mem® I.
- b. For 175 cm² flasks: transfect 6×10^6 cells with 10–25 µg DNA, 40 to 100 µL FuGENE® 6, and 1 mL of Opti-Mem® I.

²Assays are done with 3 technical replicates in order to calculate a standard deviation for each experimental variable. Each assay is repeated at least 3 independent times, yielding 3 biological replicates.

4. Day 4 – Determine the transfection efficiency: Two days post-transfection (d2) (Figure 1B), trypsinize the hrGFP-transfected cells and collect the cells from each well in separate microcentrifuge tubes (see Note 3). Spin the cells at 2000×g at 4°C for 5 minutes and aspirate the medium. Wash the cells in 1× PBS, spin at 2000×g at 4°C for 5 minutes, then aspirate the PBS. Resuspend the cell pellet in 250 to 500 µL 1× PBS. Determine the number (*i.e.*, percentage) of hrGFP-expressing cells, gating for live cells, on a flow cytometer such as an Accuri Flow Cytometer (see Note 4). The number of live cells that express hrGFP serves as an indication of the percentage of cells successfully transfected with plasmids (*i.e.*, transfection efficiency).
5. Days 5–16 – Select cells for retrotransposition events: Begin drug selection 3 days post-transfection (d3) and continue until 14 days post-transfection (d14) (Figure 1B).
 - a. For *mneoI*-based assays, add 400 µg/mL G418 to the HeLa-JVM DMEM growth medium. Change the G418-containing medium every day until 14 days post-transfection (d14).
 - b. For *mblastI*-based assays, add 10 µg/mL blasticidin S-HCl to HeLa-JVM DMEM growth medium and change the blasticidin S-HCl-containing medium once at 8 days post-transfection (d8) (see Note 5).
 - c. For *mEGFP1*-based assays, add 5 µg/mL puromycin to HeLa-JVM DMEM growth medium. Change the puromycin-containing medium every other day until 9 days post-transfection (d9) to select for cells that have the L1 expression plasmid.
6. Quantification of the LINE-1 retrotransposition assay
 - a. For *mneoI* and *mblastI* assays, 14 days post-transfection (d14) rinse the cells with 1× PBS and fix the cells (using Fix solution 2.3-1) for 30 minutes to 1 hour at room temperature or longer at 4°C. Rinse the cells in water and

³Typically, co-transfect 1 µg L1 plasmid and 0.5 µg hrGFP plasmid for each well of a 6-well plate to calculate transfection efficiency. A mock-transfected cell sample should always be included to properly gate true GFP-expressing and non-expressing cells. Using *mEGFP1* does not interfere with detection of hrGFP expression because GFP expression from *mEGFP1* resulting from retrotransposition is detectable between 7 to 9 days post-transfection (d7–d9) (66). GFP expression from hrGFP is detectable 1 to 3 days post transfection (d1–d3). Importantly, GFP expression from the retrotransposed *mEGFP1* reporter cassette is analyzed in cells transfected without hrGFP, as these transfections are done in parallel. Alternatively, a plasmid expressing mCherry can be used to determine transfection efficiency.

⁴Retrotransposition efficiency can only be calculated from cells that are transfected with an L1 construct. It is important to account for slight variations in transfection efficiencies when calculating retrotransposition efficiencies. Use of Lipofectamine® (Life Technologies) also has been reported for L1 studies, following manufacturer's directions (24). Transfection efficiencies will vary among cell lines.

⁵Blasticidin S selection was previously reported as starting 5 days post-transfection (d5) in Chinese hamster ovary cells (36). Selection with blasticidin S should be optimized when using different cell lines. HeLa-JVM cells die sooner under blasticidin S-selection than G418-selection. Blasticidin S-resistant colonies can be fixed and stained 10 to 12 days post-transfection (d10–d12).

stain (using one of the 3 Stain solutions 2.3-2) at room temperature for 1 hour. Rinse the cells with water and let dry (see Note 5). Count the stained foci in each well.

- b. For *mEGFP1* assays, 9 days post-transfection (d9), trypsinize the cells and collect the cells from each well in separate microcentrifuge tubes. Collect the cells by centrifugation at 2000×g at 4°C for 5 minutes. Aspirate the medium. Rinse the cells with 1× PBS and spin the cells again at 2000×g at 4°C for 5 minutes. Aspirate the PBS and resuspend the cell pellet in 250 to 500 µL 1× PBS. Analyze the number of EGFP-expressing cells, gating for live cells, on a flow cytometer such as an Accuri Flow Cytometer. The number of live cells that express EGFP serves as an indication of the number of cells that have successfully undergone a round of *de novo* retrotransposition.

7. To calculate the retrotransposition efficiency, drug-resistant colonies or EGFP-expressing cells are counted and adjusted for transfection efficiency (see Note 6).

- a. For G418- or blasticidin S-resistant colonies, calculate the mean colony counts (from step 3.1–6a) for the 3 wells of the same transfection condition (3 technical replicates). To calculate the adjusted retrotransposition mean, divide the mean colony counts and the standard deviation by the transfection efficiency (calculated in step 3.1–4) (see Note 6). To express the adjusted retrotransposition values as a percentage of the wild type control, divide the adjusted retrotransposition mean of an experimental sample (*e.g.*, the number of retrotransposition events generated from a mutant L1 expression construct) by the adjusted retrotransposition mean of wild type L1 (*e.g.*, pJM101/L1.3) and then multiply by 100 (see Note 7) to calculate the retrotransposition efficiency.
- b. For EGFP-expressing cells, divide the mean percentage of EGFP-expressing cells (calculated in step 3.1–6b) and the standard deviation from 3 wells per transfection condition (3 technical replicates) by the transfection efficiency (calculated in step 3.1–4) to calculate the adjusted retrotransposition mean (see Note 6). The adjusted

⁶Adjusted retrotransposition mean = (average number of drug-resistant colonies)/(fraction of hrGFP-positive cells).

⁷Retrotransposition efficiency = $100 \times (\text{adjusted retrotransposition mean}) / (\text{adjusted retrotransposition mean of the wild type L1})$. For example, if the adjusted retrotransposition mean of wild type L1 is 88, then the retrotransposition efficiency is $100 \times (88/88) = 100\%$. Similarly, if the adjusted retrotransposition efficiency of an EN mutant L1 from the same experiment is 1, then the retrotransposition efficiency of the EN mutant L1 is $100 \times (1/88) = 1.1\%$.

retrotransposition mean for *mEGFP1* retrotransposition assays represents the percentage of puromycin-resistant cells that express EGFP. Again, at least 3 biological replicates should be done per experiment. It is advisable to repeat the experiment at least three times on different days.

3.2 Alu retrotransposition assay in HeLa-HA cells (*in trans*)

Retrotransposition *in trans* occurs at a lower frequency than *in cis* (43, 51). Therefore, the retrotransposition assay detailed above is scaled-up. Please note that transfection conditions need to be optimized when using larger tissue culture plates or flasks.

1. Day 1 - Plate cells: Seed 5×10^5 HeLa-HA cells in 10 cm tissue culture dish or T-75 flask in HeLa-HA MEM growth media.
2. Day 2 - Transfect cells: Cells typically are transfected 14 to 16 hours post-plating, day zero (d0) (Figure 1B), using the FuGENE® 6 transfection reagent following the manufacturer's instructions. To assay for Alu retrotransposition, prepare a transfection mix containing 4 µg of a reporter plasmid (*e.g.*, pAlu-neo^{Tet}), 4 µg driver plasmid (*e.g.*, pCEP5' UTR-ORF2p neo; Figure 2), and 24 to 32 µL of FuGENE® 6 in 500 µL of Opti-Mem® I. Incubate the solution at room temperature for 20 minutes. Add the transfection mix to the growth medium of the cells in the tissue culture dish or flask. To determine transfection efficiencies, prepare a transfection mix containing 0.5 µg each of the reporter plasmid, the driver plasmid, and hrGFP plasmid and 4 to 6 µL of FuGENE® 6 in 100 µL of Opti-Mem® I. Incubate the transfection mix at room temperature for 20 minutes. Transfect cells with the hrGFP-containing transfection mix in 6-well plates as stated in step 3.1-2.
3. Day 3 – Stop the transfection: Approximately 24 hours post-transfection, one day post-transfection (d1) (Figure 1B), aspirate the medium from the cells and add fresh HeLa-HA MEM growth medium to the cells.
4. Day 4 – Determine the transfection efficiency: same as step 3.1–4.
5. Days 5–16 – Select the cells for retrotransposition events: same as 3.1–5a.
6. Quantitate the LINE-1 retrotransposition assay: same as 3.1–6a.
7. Calculate the retrotransposition efficiency: same as 3.1–7a.

3.3 LINE-1 retrotransposition assay co-transfected with cDNAs

The experimental design is similar to the assay above except cells are transfected with an L1 and a cDNA expression construct. When co-transfecting an L1 plasmid with a cDNA expression construct, it is essential to monitor side effects of cDNA overexpression. In order to monitor potential cDNA off-target effects, HeLa cells should also be co-transfected with the cDNA expression plasmid and a control reporter plasmid that expresses an intact copy of the same selectable marker (*i.e.*, no intron disrupting the reporter) as the LINE-1 retrotransposition plasmid. The LINE-1 retrotransposition assay and control reporter assay

must be done in parallel (*i.e.*, at the same time) (79, 80). For example, the effect of APOBEC3A (A3A) on LINE-1 retrotransposition (*mneoI* reporter cassette) and on a control reporter plasmid (pU6iNEO), as described in Richardson *et al.*, is described below (79). Retrotransposition efficiency is corrected to the reporter control assay (see Note 8).

1. Day 1 - Plate cells: Seed 2×10^4 HeLa-JVM cells in each well of a 6-well tissue culture plate in HeLa-JVM DMEM growth medium as stated above in step 3.1-1 (see Note 1).
2. Day 2 - Transfect cells: Cells typically are transfected 14 to 16 hours post-plating, day zero (d0) (Figure 1B), using the FuGENE® 6 transfection reagent following to the manufacturer's instructions. Experimental conditions for L1 transfection include: 1) pCEP4 plus pK $_{\beta}$ -arrestin; 2) pJM101/L1.3 plus pK $_{\beta}$ -arrestin, (which has no significant effect on LINE-1 retrotransposition and is a control for the co-transfected cDNA) (78); 3) pJM101/L1.3 plus pK $_{A3A}$; 4) pJM105/L1.3 plus pK $_{\beta}$ -arrestin or pK $_{A3A}$; and 5) mock transfected cells or cells transfected only with pCEP4. In parallel, experimental conditions for the reporter control plasmid include: 1) pU6iNEO plus pK $_{\beta}$ -arrestin and 2) pU6iNEO plus pK $_{A3A}$. Prepare a transfection mix in a 1.5 mL microcentrifuge tube containing either an L1 expression or control vector (0.5 μ g of the pCEP4 vector, 0.5 μ g of an L1 expression plasmid, or 0.5 μ g pU6iNEO) and a cDNA expression vector (0.5 μ g pK $_{\beta}$ -arrestin or 0.5 μ g of an pK $_{A3A}$ expression plasmid) with 3 to 4 μ L of FuGENE® 6 in 100 μ L of Opti-Mem® I. Incubate the solution at room temperature for 20 minutes. Add the transfection mix to the growth medium of one well of cells in a 6-well tissue culture plate. To calculate the transfection efficiency, prepare a transfection mix in a 1.5 mL microcentrifuge tube containing the above reagents and 0.5 μ g of an hrGFP expression plasmid (as described above in section 3.1-2).
3. Day 3 – Stop the transfection: Approximately 24 hours post-transfection, one day post-transfection (d1) (Figure 1B), aspirate the medium from the cells and add fresh HeLa-JVM DMEM growth medium to the cells.
4. Day 4 – Determine the transfection efficiency: same as step 3.1–4.
5. Days 5–16 - Select the cells for retrotransposition events: same as 3.1–5a.
6. Determine the LINE-1 retrotransposition efficiency and the effect of cDNA expression on the ability of the reporter construct (pU6iNEO) to form drug resistant foci: same as 3.1–6a.

⁸Corrected retrotransposition mean = (adjusted L1 plus expression plasmid retrotransposition mean)/(mean number of colonies from the reporter control plus the same expression plasmid). For example, the corrected retrotransposition mean of L1+pK $_{\beta}$ -arrestin is calculated by dividing the adjusted retrotransposition mean of L1+pK $_{\beta}$ -arrestin by the mean number of colonies from pU6iNEO+pK $_{\beta}$ -arrestin. Similarly, the corrected retrotransposition mean of L1+pK $_{A3A}$ is calculated by dividing the adjusted retrotransposition mean of L1+pK $_{A3A}$ by the mean number of colonies from pU6iNEO+ pK $_{A3A}$.

7. To calculate the corrected retrotransposition mean, the adjusted retrotransposition mean of L1 plus pK_β-arrestin is divided by the adjusted retrotransposition mean of pU6iNEO plus pK_β-arrestin (see Note 8). Similarly, the adjusted retrotransposition mean of L1 plus pK_A3A is divided by the adjusted retrotransposition mean of pU6iNEO plus pK_A3A. This corrected calculation accounts for any cytotoxic or off-target effects pK_A3A may have on the cell.
8. To calculate the corrected retrotransposition efficiency, divide the corrected retrotransposition mean of L1 plus pK_A3A expression vector by the corrected retrotransposition mean of L1 plus pK_β-arrestin and multiply by 100 (see Note 9). The retrotransposition efficiency reported reflects the specific inhibition of pK_A3A on LINE-1 (see Note 10).

Acknowledgments

The authors would like to thank Nancy Leff for helpful comments during the preparation of this manuscript. This work was supported in part by NIH grant GM060518 to J.V.M. Authors were supported in part by fellowships from the American Cancer Society #PF-07-059-01GMC (H.C.K.), NIGMS #5-T32-GM07544 (P.A.L. and S.R.R.) and NIGMS #T32-GM007315 (J.B.M.). J.V.M. is an Investigator of the Howard Hughes Medical Institute.

Conflict of Interest

J.V.M. is an inventor on the patent: "Kazazian, H.H., Boeke, J.D., Moran, J.V., and Dombrowski, B.A. Compositions and methods of use of mammalian retrotransposons. Application No. 60/006,831; Patent No. 6,150,160; Issued November 21, 2000." J.V.M. has not made any money from this patent and voluntarily discloses this information.

References

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissole SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM,

⁹Corrected retrotransposition efficiency = $100 \times (\text{corrected retrotransposition mean for L1 plus cDNA expression plasmid}) / (\text{corrected retrotransposition mean of the wild type L1 plus an empty vector or pK}_\beta\text{-arrestin expression plasmid control})$.

¹⁰Co-transfections involving cDNAs expressing host factors must be assayed for off-target effects (e.g., cell toxicity) before interpreting the effects on retrotransposition. For example, overexpression of A3A decreases the number of G418-resistant colonies in cells co-transfected with a control G418-resistance plasmid (pU6iNEO), but dramatically decreases the number of G418-resistant colonies in cells co-transfected with an L1/*mneoI* plasmid (79) (Figure 3). A possible interpretation of these data is that the decrease in LINE-1 retrotransposition is due to the cytotoxicity of A3A overexpression. However, the cytotoxic effects of A3A overexpression are not solely responsible for the reduction in LINE-1 retrotransposition (LINE-1/*mneoI* plus A3A) because the retrotransposition efficiency is corrected to the control plasmid (pU6iNEO plus A3A) to account for the A3A cytotoxic contribution. This correction of the data reveals a clearer representation of the specific effect of A3A on LINE-1 retrotransposition by accounting for the non-specific, off-target effects of A3A overexpression. Testing the same conditions on a non-L1 plasmid containing the same selectable or screenable marker (i.e., GFP or drug-resistance, respectively) would account for any indirect, off-target effects from data interpretation.

Correll JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blocker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kasprzyk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowski J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ. Initial sequencing and analysis of the human genome. *Nature*. 2001; 409:860–921. [PubMed: 11237011]

2. Beck CR, Garcia-Perez JL, Badge RM, Moran JV. LINE-1 elements in structural variation and disease. *Annu Rev Genomics Hum Genet*. 2011; 12:187–215. [PubMed: 21801021]
3. Dombroski BA, Mathias SL, Nanthakumar E, Scott AF, Kazazian HH Jr. Isolation of an active human transposable element. *Science*. 1991; 254:1805–1808. [PubMed: 1662412]
4. Scott AF, Schmeckpeper BJ, Abdelrazik M, Comey CT, O'Hara B, Rossiter JP, Cooley T, Heath P, Smith KD, Margolet L. Origin of the human L1 elements: proposed progenitor genes deduced from a consensus DNA sequence. *Genomics*. 1987; 1:113–125. [PubMed: 3692483]
5. Athanikar JN, Badge RM, Moran JV. A YY1-binding site is required for accurate human LINE-1 transcription initiation. *Nucleic Acids Res*. 2004; 32:3846–3855. [PubMed: 15272086]
6. Becker KG, Swergold GD, Ozato K, Thayer RE. Binding of the ubiquitous nuclear transcription factor YY1 to a cis regulatory sequence in the human LINE-1 transposable element. *Hum Mol Genet*. 1993; 2:1697–1702. [PubMed: 8268924]
7. Swergold GD. Identification, characterization, and cell specificity of a human LINE-1 promoter. *Mol Cell Biol*. 1990; 10:6718–6729. [PubMed: 1701022]
8. Speck M. Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. *Mol Cell Biol*. 2001; 21:1973–1985. [PubMed: 11238933]
9. Callahan KE, Hickman AB, Jones CE, Ghirlardo R, Furano AV. Polymerization and nucleic acid-binding properties of human L1 ORF1 protein. *Nucleic Acids Res*. 2012; 40:813–827. [PubMed: 21937507]
10. Hohjoh H, Singer MF. Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA. *EMBO J*. 1996; 15:630–639. [PubMed: 8599946]
11. Hohjoh H, Singer MF. Ribonuclease and high salt sensitivity of the ribonucleoprotein complex formed by the human LINE-1 retrotransposon. *J Mol Biol*. 1997; 271:7–12. [PubMed: 9300051]
12. Holmes SE, Singer MF, Swergold GD. Studies on p40, the leucine zipper motif-containing protein encoded by the first open reading frame of an active human LINE-1 transposable element. *J Biol Chem*. 1992; 267:19765–19768. [PubMed: 1328181]
13. Khazina E, Weichenrieder O. Non-LTR retrotransposons encode noncanonical RRM domains in their first open reading frame. *Proc Natl Acad Sci U S A*. 2009; 106:731–736. [PubMed: 19139409]
14. Kolosha VO, Martin SL. In vitro properties of the first ORF protein from mouse LINE-1 support its role in ribonucleoprotein particle formation during retrotransposition. *Proc Natl Acad Sci U S A*. 1997; 94:10155–10160. [PubMed: 9294179]
15. Kolosha VO, Martin SL. High-affinity, non-sequence-specific RNA binding by the open reading frame 1 (ORF1) protein from long interspersed nuclear element 1 (LINE-1). *J Biol Chem*. 2003; 278:8112–8117. [PubMed: 12506113]

16. Martin SL. Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal carcinoma cells. *Mol Cell Biol.* 1991; 11:4804–4807. [PubMed: 1715025]
17. Martin SL, Bushman FD. Nucleic acid chaperone activity of the ORF1 protein from the mouse LINE-1 retrotransposon. *Mol Cell Biol.* 2001; 21:467–475. [PubMed: 11134335]
18. Doucet AJ, Hulme AE, Sahinovic E, Kulpa DA, Moldovan JB, Kopera HC, Athanikar JN, Hasnaoui M, Bucheton A, Moran JV, Gilbert N. Characterization of LINE-1 ribonucleoprotein particles. *PLoS Genet.* 2010; 6
19. Ergun S, Buschmann C, Heukeshoven J, Dammann K, Schnieders F, Lauke H, Chalajour F, Kilic N, Stratling WH, Schumann GG. Cell type-specific expression of LINE-1 open reading frames 1 and 2 in fetal and adult human tissues. *J Biol Chem.* 2004; 279:27753–27763. [PubMed: 15056671]
20. Feng Q, Moran JV, Kazazian HH Jr, Boeke JD. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. *Cell.* 1996; 87:905–916. [PubMed: 8945517]
21. Goodier JL, Ostertag EM, Engleka KA, Seleme MC, Kazazian HH Jr. A potential role for the nucleolus in L1 retrotransposition. *Hum Mol Genet.* 2004; 13:1041–1048. [PubMed: 15028673]
22. Hattori M, Kuhara S, Takenaka O, Sakaki Y. L1 family of repetitive DNA sequences in primates may be derived from a sequence encoding a reverse transcriptase-related protein. *Nature.* 1986; 321:625–628. [PubMed: 2423883]
23. Mathias SL, Scott AF, Kazazian HH Jr, Boeke JD, Gabriel A. Reverse transcriptase encoded by a human transposable element. *Science.* 1991; 254:1808–1810. [PubMed: 1722352]
24. Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, Kazazian HH Jr. High frequency retrotransposition in cultured mammalian cells. *Cell.* 1996; 87:917–927. [PubMed: 8945518]
25. Taylor MS, Lacava J, Mita P, Molloy KR, Huang CR, Li D, Adney EM, Jiang H, Burns KH, Chait BT, Rout MP, Boeke JD, Dai L. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. *Cell.* 2013; 155:1034–1048. [PubMed: 24267889]
26. Fanning T, Singer M. The LINE-1 DNA sequences in four mammalian orders predict proteins that conserve homologies to retrovirus proteins. *Nucleic Acids Res.* 1987; 15:2251–2260. [PubMed: 3562227]
27. Moran JV. Human L1 retrotransposition: insights and peculiarities learned from a cultured cell retrotransposition assay. *Genetica.* 1999; 107:39–51. [PubMed: 10952196]
28. Moran JV, DeBerardinis RJ, Kazazian HH Jr. Exon shuffling by L1 retrotransposition. *Science.* 1999; 283:1530–1534. [PubMed: 10066175]
29. Perepelitsa-Belancio V, Deininger P. RNA truncation by premature polyadenylation attenuates human mobile element activity. *Nat Genet.* 2003; 35:363–366. [PubMed: 14625551]
30. Usdin K, Furano AV. The structure of the guanine-rich polypurine:polypyrimidine sequence at the right end of the rat L1 (LINE) element. *J Biol Chem.* 1989; 264:15681–15687. [PubMed: 2768282]
31. Luan DD, Korman MH, Jakubczak JL, Eickbush TH. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. *Cell.* 1993; 72:595–605. [PubMed: 7679954]
32. Cost GJ, Feng Q, Jacquier A, Boeke JD. Human L1 element target-primed reverse transcription in vitro. *EMBO J.* 2002; 21:5899–5910. [PubMed: 12411507]
33. Gilbert N, Lutz S, Morrish TA, Moran JV. Multiple fates of L1 retrotransposition intermediates in cultured human cells. *Mol Cell Biol.* 2005; 25:7780–7795. [PubMed: 16107723]
34. Gilbert N, Lutz-Prigge S, Moran JV. Genomic deletions created upon LINE-1 retrotransposition. *Cell.* 2002; 110:315–325. [PubMed: 12176319]
35. Jurka J. Sequence patterns indicate an enzymatic involvement in integration of mammalian retrotransposons. *Proc Natl Acad Sci U S A.* 1997; 94:1872–1877. [PubMed: 9050872]
36. Morrish TA, Gilbert N, Myers JS, Vincent BJ, Stamato TD, Taccioli GE, Batzer MA, Moran JV. DNA repair mediated by endonuclease-independent LINE-1 retrotransposition. *Nat Genet.* 2002; 31:159–165. [PubMed: 12006980]
37. Grimaldi G, Skowronski J, Singer MF. Defining the beginning and end of KpnI family segments. *EMBO J.* 1984; 3:1753–1759. [PubMed: 6090124]

38. Symer DE, Connelly C, Szak ST, Caputo EM, Cost GJ, Parmigiani G, Boeke JD. Human L1 retrotransposition is associated with genetic instability in vivo. *Cell*. 2002; 110:327–338. [PubMed: 12176320]
39. Myers JS, Vincent BJ, Udall H, Watkins WS, Morrish TA, Kilroy GE, Swergold GD, Henke J, Henke L, Moran JV, Jorde LB, Batzer MA. A comprehensive analysis of recently integrated human Ta L1 elements. *Am J Hum Genet*. 2002; 71:312–326. [PubMed: 12070800]
40. Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE, Badge RM, Moran JV. LINE-1 retrotransposition activity in human genomes. *Cell*. 2010; 141:1159–1170. [PubMed: 20602998]
41. Buzdin A, Gogvadze E, Kovalskaya E, Volchkov P, Ustyugova S, Illarionova A, Fushan A, Vinogradova T, Sverdlov E. The human genome contains many types of chimeric retrogenes generated through in vivo RNA recombination. *Nucleic Acids Res*. 2003; 31:4385–4390. [PubMed: 12888497]
42. Buzdin A, Ustyugova S, Gogvadze E, Vinogradova T, Lebedev Y, Sverdlov E. A new family of chimeric retrotranscripts formed by a full copy of U6 small nuclear RNA fused to the 3' terminus of L1. *Genomics*. 2002; 80:402–406. [PubMed: 12376094]
43. Dewannieux M, Esnault C, Heidmann T. LINE-mediated retrotransposition of marked Alu sequences. *Nat Genet*. 2003; 35:41–48. [PubMed: 12897783]
44. Dewannieux M, Heidmann T. L1-mediated retrotransposition of murine B1 and B2 SINEs recapitulated in cultured cells. *J Mol Biol*. 2005; 349:241–247. [PubMed: 15890192]
45. Esnault C, Maestre J, Heidmann T. Human LINE retrotransposons generate processed pseudogenes. *Nat Genet*. 2000; 24:363–367. [PubMed: 10742098]
46. Garcia-Perez JL, Doucet AJ, Bucheton A, Moran JV, Gilbert N. Distinct mechanisms for trans-mediated mobilization of cellular RNAs by the LINE-1 reverse transcriptase. *Genome Res*. 2007; 17:602–611. [PubMed: 17416749]
47. Hancks DC, Goodier JL, Mandal PK, Cheung LE, Kazazian HH Jr. Retrotransposition of marked SVA elements by human L1s in cultured cells. *Hum Mol Genet*. 2011; 20:3386–3400. [PubMed: 21636526]
48. Hancks DC, Mandal PK, Cheung LE, Kazazian HH Jr. The minimal active human SVA retrotransposon requires only the 5'-hexamer and Alu-like domains. *Mol Cell Biol*. 2012; 32:4718–4726. [PubMed: 23007156]
49. Raiz J, Damert A, Chira S, Held U, Klawitter S, Hamdorf M, Lower J, Stratling WH, Lower R, Schumann GG. The non-autonomous retrotransposon SVA is trans-mobilized by the human LINE-1 protein machinery. *Nucleic Acids Res*. 2012; 40:1666–1683. [PubMed: 22053090]
50. Weber MJ. Mammalian small nucleolar RNAs are mobile genetic elements. *PLoS Genet*. 2006; 2:e205. [PubMed: 17154719]
51. Wei W, Gilbert N, Ooi SL, Lawler JF, Ostertag EM, Kazazian HH, Boeke JD, Moran JV. Human L1 retrotransposition: cis preference versus trans complementation. *Mol Cell Biol*. 2001; 21:1429–1439. [PubMed: 11158327]
52. Kazazian HH Jr, Wong C, Youssoufian H, Scott AF, Phillips DG, Antonarakis SE. Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. *Nature*. 1988; 332:164–166. [PubMed: 2831458]
53. Hancks DC, Kazazian HH Jr. Active human retrotransposons: variation and disease. *Curr Opin Genet Dev*. 2012; 22:191–203. [PubMed: 22406018]
54. Boeke JD, Garfinkel DJ, Styles CA, Fink GR. Ty elements transpose through an RNA intermediate. *Cell*. 1985; 40:491–500. [PubMed: 2982495]
55. Curcio MJ, Garfinkel DJ. Single-step selection for Ty1 element retrotransposition. *Proc Natl Acad Sci U S A*. 1991; 88:936–940. [PubMed: 1846969]
56. Heidmann T, Heidmann O, Nicolas JF. An indicator gene to demonstrate intracellular transposition of defective retroviruses. *Proc Natl Acad Sci U S A*. 1988; 85:2219–2223. [PubMed: 2832848]
57. Freeman JD, Goodchild NL, Mager DL. A modified indicator gene for selection of retrotransposition events in mammalian cells. *Biotechniques*. 1994; 17:46, 48–49, 52. [PubMed: 7946311]

58. Wei W, Morrish TA, Alisch RS, Moran JV. A transient assay reveals that cultured human cells can accommodate multiple LINE-1 retrotransposition events. *Anal Biochem.* 2000; 284:435–438. [PubMed: 10964437]
59. Coufal NG, Garcia-Perez JL, Peng GE, Marchetto MC, Muotri AR, Mu Y, Carson CT, Macia A, Moran JV, Gage FH. Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells. *Proc Natl Acad Sci U S A.* 2011; 108:20382–20387. [PubMed: 22159035]
60. Coufal NG, Garcia-Perez JL, Peng GE, Yeo GW, Mu Y, Lovci MT, Morell M, O'Shea KS, Moran JV, Gage FH. L1 retrotransposition in human neural progenitor cells. *Nature.* 2009; 460:1127–1131. [PubMed: 19657334]
61. Garcia-Perez JL, Morell M, Scheys JO, Kulpa DA, Morell S, Carter CC, Hammer GD, Collins KL, O'Shea KS, Menendez P, Moran JV. Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. *Nature.* 2010; 466:769–773. [PubMed: 20686575]
62. Kubo S, Seleme MC, Soifer HS, Perez JL, Moran JV, Kazazian HH Jr, Kasahara N. L1 retrotransposition in nondividing and primary human somatic cells. *Proc Natl Acad Sci U S A.* 2006; 103:8036–8041. [PubMed: 16698926]
63. Muotri AR, Chu VT, Marchetto MC, Deng W, Moran JV, Gage FH. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. *Nature.* 2005; 435:903–910. [PubMed: 15959507]
64. Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, Nakashima K, Gage FH. L1 retrotransposition in neurons is modulated by MeCP2. *Nature.* 2010; 468:443–446. [PubMed: 21085180]
65. Ostertag EM, DeBerardinis RJ, Goodier JL, Zhang Y, Yang N, Gerton GL, Kazazian HH Jr. A mouse model of human L1 retrotransposition. *Nat Genet.* 2002; 32:655–660. [PubMed: 12415270]
66. Ostertag EM, Prak ET, DeBerardinis RJ, Moran JV, Kazazian HH Jr. Determination of L1 retrotransposition kinetics in cultured cells. *Nucleic Acids Res.* 2000; 28:1418–1423. [PubMed: 10684937]
67. Kopera HC, Moldovan JB, Morrish TA, Garcia-Perez JL, Moran JV. Similarities between long interspersed element-1 (LINE-1) reverse transcriptase and telomerase. *Proc Natl Acad Sci U S A.* 2011; 108:20345–20350. [PubMed: 21940498]
68. Morrish TA, Garcia-Perez JL, Stamato TD, Taccioli GE, Sekiguchi J, Moran JV. Endonuclease-independent LINE-1 retrotransposition at mammalian telomeres. *Nature.* 2007; 446:208–212. [PubMed: 17344853]
69. Goodier JL, Zhang L, Vetter MR, Kazazian HH Jr. LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex. *Mol Cell Biol.* 2007; 27:6469–6483. [PubMed: 17562864]
70. Xie Y, Rosser JM, Thompson TL, Boeke JD, An W. Characterization of L1 retrotransposition with high-throughput dual-luciferase assays. *Nucleic Acids Res.* 2011; 39:e16. [PubMed: 21071410]
71. Rangwala SH, Kazazian HH Jr. The L1 retrotransposition assay: a retrospective and toolkit. *Methods.* 2009; 49:219–226. [PubMed: 19398011]
72. Hulme AE, Bogerd HP, Cullen BR, Moran JV. Selective inhibition of Alu retrotransposition by APOBEC3G. *Gene.* 2007; 390:199–205. [PubMed: 17079095]
73. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, Kazazian HH Jr. Hot L1s account for the bulk of retrotransposition in the human population. *Proc Natl Acad Sci U S A.* 2003; 100:5280–5285. [PubMed: 12682288]
74. Sassaman DM, Dombroski BA, Moran JV, Kimberland ML, Naas TP, DeBerardinis RJ, Gabriel A, Swergold GD, Kazazian HH Jr. Many human L1 elements are capable of retrotransposition. *Nat Genet.* 1997; 16:37–43. [PubMed: 9140393]
75. Brouha B, Meischl C, Ostertag E, de Boer M, Zhang Y, Neijens H, Roos D, Kazazian HH Jr. Evidence consistent with human L1 retrotransposition in maternal meiosis I. *Am J Hum Genet.* 2002; 71:327–336. [PubMed: 12094329]
76. Garcia-Perez JL, Marchetto MC, Muotri AR, Coufal NG, Gage FH, O'Shea KS, Moran JV. LINE-1 retrotransposition in human embryonic stem cells. *Hum Mol Genet.* 2007; 16:1569–1577. [PubMed: 17468180]

77. Alisch RS, Garcia-Perez JL, Muotri AR, Gage FH, Moran JV. Unconventional translation of mammalian LINE-1 retrotransposons. *Genes Dev.* 2006; 20:210–224. [PubMed: 16418485]
78. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. *Proc Natl Acad Sci U S A.* 2006; 103:8780–8785. [PubMed: 16728505]
79. Richardson SR, Narvaiza I, Planegger RA, Weitzman MD, Moran JV. APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. *Elife.* 2014; 3:e02008. [PubMed: 24843014]
80. Moldovan JB, Moran JV. The zinc-finger antiviral protein ZAP inhibits LINE and Alu retrotransposition. *PLoS Genet.* 2015 accepted for publication.
81. Esnault C, Casella JF, Heidmann T. A *Tetrahymena thermophila* ribozyme-based indicator gene to detect transposition of marked retroelements in mammalian cells. *Nucleic Acids Res.* 2002; 30:e49. [PubMed: 12034850]

Figure 1. LINE-1 Retrotransposition Assay

(A) A full-length retrotransposition-competent LINE-1 contains the *mneoI* reporter cassette (orange box) in the 3'UTR in the opposite orientation with respect to LINE-1 (pJM101/L.13) transcription. The reporter gene, neomycin phosphotransferase (backwards NEO) is interrupted by an intron (hatched box), which is in the same orientation with respect to LINE-1 transcription. The reporter cassette has its own promoter (upside down black arrow) and polyadenylation signal (upside down small black lollipop). The pCEP4 plasmid backbone encodes for the EBNA-1 (EBNA-1) viral protein and contains an origin of viral replication (oriP) and hygromycin B-resistance gene (HYG^R) for plasmid replication and hygromycin-selection, respectively, in mammalian cultured cells. The backbone also has a bacterial origin of replication (ori) and an ampicillin-resistance gene (AMP^R) for replication and ampicillin-selection, respectively, in *E.coli*. The LINE-1 is transcribed from the CMV

promoter (black triangle labeled “CMV”) or its promoter in the 5’UTR (gray arrow) and transcription is terminated at an SV40 polyadenylation signal (large black lollipop). Once transcribed, L1 ORF1p (yellow circles) and ORF2p (blue circle) are translated from the L1 mRNA (grey, yellow, blue, and orange line followed by “AAAA_n”) and the intron is spliced out. Only upon reverse transcription and integration into a genomic locus (5’ truncated blue and orange box), which is flanked by target-site duplications (TSD, red wavy lines), can the NEO gene be expressed to confer drug-resistance. **(B)** A timeline of the assay is depicted and described in the Methods. Days of the protocol are noted above and the corresponding days post-transfection (d0–14) are noted below. The end result of the assay is depicted under d14. The pJJ101/L1.3 construct is a wild type LINE-1 with a blasticidin deaminase (*mblastI*) reporter cassette and its retrotransposition results in many drug-resistant colonies. The pJJ105/L1.3 construct contains a LINE-1 reverse transcriptase mutant, cannot complete retrotransposition, and does not result in any drug-resistant colonies.

Figure 2. Alu Retrotransposition (*trans*-complementation) Assay

Retrotransposition of Alu requires the LINE-1 ORF2 protein (43). For the Alu *trans*-complementation assay, the reporter plasmid contains the Alu sequence (light blue box) and is tagged with a modified NEO retrotransposition indicator cassette (neo^{Tet}) interrupted by a self-splicing group I intron (checkered box) (81). The neo^{Tet} cassette is followed by a variably sized poly A tail (A_n) and the RNA pol III terminator sequence (red lollipop). The Alu plasmid must be co-transfected with a plasmid (pCEP5'UTR-ORF2p neo) expressing LINE-1 ORF2p (blue circle) to detect retrotransposition in HeLa cells. The resulting G418-resistant colonies generally contain *de novo* full-length Alu retrotransposition events flanked by target-site duplications (TSD, red wavy lines).

Figure 3. Co-transfection of LINE-1 with cDNAs

The LINE-1 retrotransposition assay is carried out as described in Figure 1 except that a plasmid expressing pK_A3A (purple box) is co-transfected with a LINE-1 expression construct (pJM101/L1.3, see Figure 1A for details). In parallel, pK_A3A is co-transfected with a reporter control, pU6iNEO, which expresses the neomycin phosphotransferase gene without the requirement for retrotransposition (*i.e.*, the neomycin phosphotransferase gene lacks an intron). Both sets of co-transfected cells are grown under drug-selection and the resulting drug-resistant colonies (dark purple circles) are counted. The parallel pU6iNEO experiment is essential to determine to what extent the effects of A3A overexpression are LINE-1 specific. Note the greater decrease in G418-resistant colonies in “LINE-1 + A3A” than “pU6iNEO + A3A” (79).